Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
Aufreinigung
SLPI Antibody is affinity chromatography purified via peptide column.
Immunogen
SLPI antibody was raised against a 17 amino acid synthetic peptide from near the center of human SLPI. The immunogen is located within amino acids 60 - 110 of SLPI.
SLPI
Reaktivität: Human
WB
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
SLPI antibody can be used for detection of SLPI by Western blot at 1 - 2 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 10 μ,g/mL.
Antibody validated: Western Blot in human samples and Immunohistochemistry in mouse samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
SLPI Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
SLPI antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
SLPI Antibody: Secretory leukocyte protease inhibitor (SLPI) is produced at mucosal surfaces, primarily the upper respiratory tract and is thought to play an important role in the antiprotease defense mechanism of the lung. SLPI forms inhibitory complexes with numerous proteolytic enzymes such as neutrophil elastase, and has been shown to possess anti-inflammatory, anti-viral, and antibacterial activities. Its expression in oral epithelial cells is stimulated by HIV-1 gp120, suggesting that SLPI is a component of the oral mucosal response to HIV-1. In peripheral blood monocytes, SLPI can inhibit NF-κ,B activation by inhibiting Iκ,B degradation in the cytoplasm and competing for NF-κ,B binding sites in the nucleus. This attenuation of the inflammatory response may also act to suppress liver metastases and other cancer cell invasions, but promote blood-borne metastasis via an invasion-independent pathway.